| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
|
N Engl J Med
|
2006
|
4.47
|
|
2
|
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.
|
Nat Genet
|
2011
|
3.37
|
|
3
|
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
|
Breast Cancer Res Treat
|
2008
|
1.82
|
|
4
|
Common breast cancer susceptibility loci are associated with triple-negative breast cancer.
|
Cancer Res
|
2011
|
1.65
|
|
5
|
Current chemotherapeutic options for the treatment of advanced bladder cancer: a review.
|
Urol Oncol
|
2010
|
1.43
|
|
6
|
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival.
|
Breast Cancer Res Treat
|
2006
|
1.43
|
|
7
|
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
Eur J Cancer
|
2008
|
1.43
|
|
8
|
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
|
BMC Cancer
|
2013
|
1.32
|
|
9
|
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.
|
Carcinogenesis
|
2013
|
1.28
|
|
10
|
Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis.
|
Liver Int
|
2013
|
1.21
|
|
11
|
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
|
Clin Cancer Res
|
2009
|
1.12
|
|
12
|
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
|
PLoS One
|
2012
|
1.12
|
|
13
|
Multifocal extranodal non-hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study.
|
Oncologist
|
2005
|
1.07
|
|
14
|
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
|
Breast Cancer Res Treat
|
2011
|
1.05
|
|
15
|
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.
|
BMC Cancer
|
2006
|
1.04
|
|
16
|
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
|
Cancer
|
2010
|
1.02
|
|
17
|
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
|
Breast Cancer Res Treat
|
2012
|
1.01
|
|
18
|
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
|
BMC Med
|
2010
|
1.00
|
|
19
|
Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas.
|
Cancer J
|
2006
|
0.98
|
|
20
|
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2006
|
0.97
|
|
21
|
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
|
Oncology
|
2009
|
0.97
|
|
22
|
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
|
Breast Cancer Res Treat
|
2005
|
0.95
|
|
23
|
Late complications of chemotherapy in testicular cancer.
|
Cancer Treat Rev
|
2010
|
0.95
|
|
24
|
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
|
Breast Cancer Res Treat
|
2011
|
0.94
|
|
25
|
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
|
BMC Cancer
|
2014
|
0.93
|
|
26
|
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
|
J Cancer Res Clin Oncol
|
2014
|
0.92
|
|
27
|
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
|
Endocr Relat Cancer
|
2012
|
0.92
|
|
28
|
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
|
Clin Breast Cancer
|
2012
|
0.91
|
|
29
|
Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
|
Clin Breast Cancer
|
2010
|
0.91
|
|
30
|
Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.
|
Cancer Treat Rev
|
2011
|
0.91
|
|
31
|
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
|
J Thorac Oncol
|
2007
|
0.91
|
|
32
|
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
|
Crit Rev Oncol Hematol
|
2008
|
0.90
|
|
33
|
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
|
BMC Cancer
|
2013
|
0.90
|
|
34
|
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
|
Breast Cancer Res
|
2012
|
0.89
|
|
35
|
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
|
J Transl Med
|
2012
|
0.89
|
|
36
|
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
|
Anticancer Res
|
2011
|
0.89
|
|
37
|
Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.
|
Cancer Treat Rev
|
2011
|
0.89
|
|
38
|
Epithelial ovarian cancer: focus on targeted therapy.
|
Crit Rev Oncol Hematol
|
2010
|
0.89
|
|
39
|
Developments in the systemic treatment of metastatic cervical cancer.
|
Cancer Treat Rev
|
2012
|
0.87
|
|
40
|
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
|
Curr Med Res Opin
|
2009
|
0.86
|
|
41
|
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
|
Support Care Cancer
|
2014
|
0.85
|
|
42
|
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
|
Breast Cancer Res Treat
|
2005
|
0.85
|
|
43
|
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
|
Anticancer Res
|
2007
|
0.85
|
|
44
|
Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature.
|
J Neurooncol
|
2005
|
0.84
|
|
45
|
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
|
Anticancer Res
|
2008
|
0.84
|
|
46
|
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
|
PLoS One
|
2013
|
0.84
|
|
47
|
Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.
|
PLoS One
|
2013
|
0.83
|
|
48
|
Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis.
|
Transpl Int
|
2012
|
0.83
|
|
49
|
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
|
Anticancer Res
|
2008
|
0.83
|
|
50
|
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma.
|
Appl Immunohistochem Mol Morphol
|
2007
|
0.83
|
|
51
|
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
|
Anticancer Res
|
2012
|
0.83
|
|
52
|
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
|
Anticancer Res
|
2005
|
0.83
|
|
53
|
Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra).
|
Int J Cardiol
|
2012
|
0.82
|
|
54
|
Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.
|
World J Gastroenterol
|
2010
|
0.82
|
|
55
|
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
|
BMC Med
|
2011
|
0.81
|
|
56
|
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.
|
PLoS One
|
2013
|
0.81
|
|
57
|
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
|
Anticancer Drugs
|
2010
|
0.81
|
|
58
|
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
|
Oncology
|
2008
|
0.81
|
|
59
|
Hepatoid pancoast tumor. A case report and review of the literature.
|
Lung Cancer
|
2012
|
0.81
|
|
60
|
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
|
Anticancer Res
|
2004
|
0.81
|
|
61
|
Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis.
|
Open Access J Urol
|
2010
|
0.80
|
|
62
|
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.
|
PLoS One
|
2013
|
0.80
|
|
63
|
Left ventricle enlargement and increased systolic velocity in the mitral valve are indirect markers of the hepatopulmonary syndrome.
|
Liver Int
|
2011
|
0.80
|
|
64
|
Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokers.
|
Oncol Lett
|
2012
|
0.80
|
|
65
|
Concomitant diagnosis of myeloproliferative neoplasm and non-Hodgkin's lymphoma in a patient with portal vein thrombosis.
|
Anticancer Res
|
2011
|
0.79
|
|
66
|
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
|
BMC Cancer
|
2012
|
0.78
|
|
67
|
Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis.
|
Eur J Gastroenterol Hepatol
|
2015
|
0.78
|
|
68
|
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
|
Eur Urol
|
2005
|
0.78
|
|
69
|
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
|
Anticancer Res
|
2012
|
0.77
|
|
70
|
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
|
Med Oncol
|
2006
|
0.77
|
|
71
|
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
|
Gynecol Oncol
|
2008
|
0.77
|
|
72
|
Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.
|
Clin Rheumatol
|
2014
|
0.77
|
|
73
|
Developments in the systemic treatment of endometrial cancer.
|
Crit Rev Oncol Hematol
|
2010
|
0.77
|
|
74
|
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
|
Oral Surg Oral Med Oral Pathol Oral Radiol
|
2012
|
0.77
|
|
75
|
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
|
Clin Colorectal Cancer
|
2013
|
0.77
|
|
76
|
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
|
Pathol Oncol Res
|
2014
|
0.76
|
|
77
|
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
|
Med Oncol
|
2007
|
0.76
|
|
78
|
Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
|
Front Oncol
|
2013
|
0.75
|
|
79
|
Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents.
|
Obstet Gynecol Int
|
2013
|
0.75
|
|
80
|
Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease.
|
J Clin Gastroenterol
|
2014
|
0.75
|
|
81
|
Two cases of complete response after imatinib mesylate treatment of advanced GIST.
|
Anticancer Res
|
2007
|
0.75
|
|
82
|
Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.
|
Am J Clin Oncol
|
2002
|
0.75
|
|
83
|
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
|
Pharmacogenomics
|
2012
|
0.75
|
|
84
|
Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
|
J Cancer Res Ther
|
2016
|
0.75
|
|
85
|
Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
|
Eur J Gastroenterol Hepatol
|
2017
|
0.75
|
|
86
|
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
|
Anticancer Res
|
2010
|
0.75
|
|
87
|
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|